ATR and ovarian carcinoma: Second, in a phase II clinical trial in platinum-resistant ovarian cancer evaluating the combination of the replication stress–inducing agents gemcitabine and an ATR inhibitor, ovarian carcinomas with high replication stress defined by genomic measures responded better to combination therapy independent of HR status (39).